These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 10579747

  • 1. Cardioprotective effect of angiotensin II receptor antagonists.
    White M.
    Can J Cardiol; 1999 Nov; 15 Suppl F():10F-4F. PubMed ID: 10579747
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.
    Suzuki H, Kanno Y, Kaneko K, Kaneko M, Kotaki S, Mimura T, Takane H.
    Ther Apher Dial; 2004 Aug; 8(4):320-7. PubMed ID: 15274684
    [Abstract] [Full Text] [Related]

  • 3. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 4. Angiotensin II type 1 receptor blockade: a novel therapeutic concept.
    Johnston CI.
    Blood Press Suppl; 2000 Oct; 1():9-13. PubMed ID: 11059629
    [Abstract] [Full Text] [Related]

  • 5. Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction.
    Sander GE, McKinnie JJ, Greenberg SS, Giles TD.
    Prog Cardiovasc Dis; 1999 Oct; 41(4):265-300. PubMed ID: 10362349
    [Abstract] [Full Text] [Related]

  • 6. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 7. Rationale for the use of combination angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy in heart failure.
    Carson PE.
    Am Heart J; 2000 Sep; 140(3):361-6. PubMed ID: 10966531
    [Abstract] [Full Text] [Related]

  • 8. [The role of the selective blocking of angiotensin II receptors in the treatment of cardiovascular diseases].
    Carnovali M.
    Clin Ter; 2001 Sep; 152(2):103-6. PubMed ID: 11441521
    [Abstract] [Full Text] [Related]

  • 9. ACE inhibitors versus AT1 blockers in the treatment of hypertension and syndrome X.
    Feldman R.
    Can J Cardiol; 2000 Aug; 16 Suppl E():41E-44E. PubMed ID: 10906626
    [Abstract] [Full Text] [Related]

  • 10. Left ventricular hypertrophy and angiotensin II receptor blocking agents.
    Yasunari K, Maeda K, Nakamura M, Watanabe T, Yoshikawa J, Hirohashi K.
    Curr Med Chem Cardiovasc Hematol Agents; 2005 Jan; 3(1):61-7. PubMed ID: 15638745
    [Abstract] [Full Text] [Related]

  • 11. [AT1 angiotensin receptor inhibition as a new therapeutic possibility].
    Hunyady L, Nagy L.
    Orv Hetil; 1997 Oct 12; 138(41):2583-90. PubMed ID: 9411327
    [Abstract] [Full Text] [Related]

  • 12. Angiotensin receptor antagonists and ACE inhibitors.
    Howes LG, Christie N.
    Aust Fam Physician; 1998 Oct 12; 27(10):914-7, 919-21. PubMed ID: 9798290
    [Abstract] [Full Text] [Related]

  • 13. Are angiotensin II receptor antagonists indicated in chronic heart failure?
    Komajda M.
    Heart Fail Monit; 2002 Oct 12; 2(3):85-7. PubMed ID: 12634889
    [Abstract] [Full Text] [Related]

  • 14. Angioedema associated with angiotensin II receptor antagonists: challenging our knowledge of angioedema and its etiology.
    Chiu AG, Krowiak EJ, Deeb ZE.
    Laryngoscope; 2001 Oct 12; 111(10):1729-31. PubMed ID: 11801934
    [Abstract] [Full Text] [Related]

  • 15. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE, Julius S.
    Am Heart J; 2004 Nov 12; 148(5):747-54. PubMed ID: 15523303
    [Abstract] [Full Text] [Related]

  • 16. Pharmacology of ACE inhibitors versus AT1 blockers.
    Vaughan D.
    Can J Cardiol; 2000 Aug 12; 16 Suppl E():36E-40E. PubMed ID: 10906625
    [Abstract] [Full Text] [Related]

  • 17. Angiotensin II type 1 receptor blockade: a new development in cardiovascular pharmacology.
    Leary AC, MacDonald TM.
    Int J Clin Pract; 1998 Oct 12; 52(7):475-81. PubMed ID: 10622089
    [Abstract] [Full Text] [Related]

  • 18. [Angiotensin II type-1-receptor antagonists from the viewpoint of nephrology].
    Hauser AC, Hörl WH.
    Wien Med Wochenschr; 2001 Oct 12; 151(7-8):160-4. PubMed ID: 11450164
    [Abstract] [Full Text] [Related]

  • 19. [Therapy of arterial hypertension with angiotensin receptor blockers].
    Nobre FL.
    Rev Port Cardiol; 1999 Apr 12; 18(4):407-12. PubMed ID: 10371849
    [Abstract] [Full Text] [Related]

  • 20. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM, Sanoski CA, Spinler SA.
    Pharmacotherapy; 2009 Jan 12; 29(1):31-48. PubMed ID: 19113795
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.